Industry organizations including the National Thoroughbred Racing Association will propose an international summit on equine medication this year in the wake of conflict over calls for the race-day ban of anti-bleeding drugs such as Salix.
A release is scheduled to be issued sometime April 20, sources said. It developed from the April 19 meeting of the Racing Medication and Testing Consortium in Dallas, Texas.
The RMTC, a group of about 25 industry stakeholders, hasn’t issued a statement or release on the Texas meeting, though it was said to be contentious. Major industry groups have come out in support of a proposal by the Association of Racing Commissioners International to phase out race-day medication—Salix and related adjunct anti-bleeding drugs—in five years, but major horsemen’s groups in particular oppose such a move and have called for further study.
The National Horsemen’s Benevolent and Protective Association said it will use its summer convention in late July to hold a forum on race-day medication.
The NTRA has not commented yet on its April 18 board meeting. Racetracks have been silent on the possibility of banning Salix and adjunct bleeder medications on race day.